- Home
- CRBP vs BTA Comparison
CRBP vs BTA Comparison
Compare CRBP & BTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- BTA
- Stock Information
- Founded
- CRBP 2009
- BTA 2006
- Country
- CRBP United States
- BTA United States
- Employees
- CRBP N/A
- BTA N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- BTA Trusts Except Educational Religious and Charitable
- Sector
- CRBP Health Care
- BTA Finance
- Exchange
- CRBP Nasdaq
- BTA Nasdaq
- Market Cap
- CRBP 114.8M
- BTA 119.9M
- IPO Year
- CRBP N/A
- BTA N/A
- Fundamental
- Price
- CRBP $9.50
- BTA $9.68
- Analyst Decision
- CRBP Strong Buy
- BTA
- Analyst Count
- CRBP 10
- BTA 0
- Target Price
- CRBP $53.22
- BTA N/A
- AVG Volume (30 Days)
- CRBP 91.8K
- BTA 21.9K
- Earning Date
- CRBP 11-06-2025
- BTA 01-01-0001
- Dividend Yield
- CRBP N/A
- BTA 5.22%
- EPS Growth
- CRBP N/A
- BTA N/A
- EPS
- CRBP N/A
- BTA N/A
- Revenue
- CRBP N/A
- BTA N/A
- Revenue This Year
- CRBP N/A
- BTA N/A
- Revenue Next Year
- CRBP $220.04
- BTA N/A
- P/E Ratio
- CRBP N/A
- BTA N/A
- Revenue Growth
- CRBP N/A
- BTA N/A
- 52 Week Low
- CRBP $4.64
- BTA $8.59
- 52 Week High
- CRBP $56.93
- BTA $10.62
- Technical
- Relative Strength Index (RSI)
- CRBP 49.85
- BTA 86.69
- Support Level
- CRBP $9.42
- BTA $8.90
- Resistance Level
- CRBP $9.73
- BTA $8.99
- Average True Range (ATR)
- CRBP 0.51
- BTA 0.09
- MACD
- CRBP -0.08
- BTA 0.08
- Stochastic Oscillator
- CRBP 15.33
- BTA 95.71
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About BTA BlackRock Long-Term Municipal Advantage Trust of Beneficial Interest
Blackrock Long-term Municipal AdtgTrust is a diversified investment fund with an investment objective to provide current income exempt from regular U.S. federal income tax. The Fund invests more of its total assets in municipal bonds, municipal securities, and derivative instruments.